Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trial.
Acute heart failure
Blood pressure
Heart failure
Medical therapy
Randomized trial
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
revised:
04
02
2024
received:
17
09
2023
accepted:
12
02
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
A high-intensity care (HIC) strategy with rapid guideline-directed medical therapy (GDMT) up-titration and close follow-up visits improved outcomes, compared to usual care (UC), in patients recently hospitalized for acute heart failure (AHF). Hypotension is a major limitation to GDMT implementation. We aimed to assess the impact of baseline systolic blood pressure (SBP) on the effects of HIC versus UC and the role of early SBP changes in STRONG-HF. A total of 1075 patients hospitalized for AHF with SBP ≥100 mmHg were included in STRONG-HF. For the purpose of this post-hoc analysis, patients were stratified by tertiles of baseline SBP (<118, 118-128, and ≥129 mmHg) and, in the HIC arm, by tertiles of changes in SBP from the values measured before discharge to those measured at 1 week after discharge (≥2 mmHg increase, ≤7 mmHg decrease to <2 mmHg increase, and ≥8 mmHg decrease). The primary endpoint was 180-day heart failure rehospitalization or death. The effect of HIC versus UC on the primary endpoint was independent of baseline SBP evaluated as tertiles (p In STRONG-HF, the benefits of HIC versus UC were independent of baseline SBP. Rapid GDMT up-titration was performed also in patients with an early SBP drop, resulting in similar 180-day outcome as compared to patients with stable or increased SBP.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Roche Diagnostics
Informations de copyright
© 2024 European Society of Cardiology.
Références
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. https://doi.org/10.1002/ejhf.2333
Cotter G, Davison B, Cohen-Solal A, Freund Y, Mebazaa A. Targeting the ‘vulnerable’ period - first 3-6 months after an acute heart failure admission - the light gets brighter. Eur J Heart Fail 2023;25:30-34. https://doi.org/10.1002/ejhf.2754
Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol 2015;12:220-229. https://doi.org/10.1038/nrcardio.2015.14
Greene SJ, Butler J, Fonarow GC. In-hospital initiation of quadruple medical therapy for heart failure: Making the post-discharge vulnerable phase far less vulnerable. Eur J Heart Fail 2022;24:227-229. https://doi.org/10.1002/ejhf.2382
Metra M, Adamo M, Tomasoni D, Mebazaa A, Bayes-Genis A, Abdelhamid M, et al. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC. Eur J Heart Fail 2023;25:1115-1131. https://doi.org/10.1002/ejhf.2888
Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial. Lancet 2022;400:1938-1952. https://doi.org/10.1016/S0140-6736(22)02076-1
Arrigo M, Biegus J, Asakage A, Mebazaa A, Davison B, Edwards C, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: A sub-analysis of the STRONG-HF randomized clinical trial. Eur J Heart Fail 2023;25:1145-1155. https://doi.org/10.1002/ejhf.2920
Čerlinskaitė-Bajorė K, Lam CSP, Sliwa K, Adamo M, ter Maaten JM, Léopold V, et al. Sex-specific analysis of the rapid up-titration of guideline-directed medical therapies after a hospitalization for acute heart failure: Insights from the STRONG-HF trial. Eur J Heart Fail 2023;25:1156-1165. https://doi.org/10.1002/ejhf.2882
Pagnesi M, Metra M, Cohen-Solal A, Edwards C, Adamo M, Tomasoni D, et al. Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction. J Am Coll Cardiol 2023;81:2131-2144. https://doi.org/10.1016/j.jacc.2023.03.426
Adamo M, Pagnesi M, Mebazaa A, Davison B, Edwards C, Tomasoni D, et al. NT-proBNP and high intensity care for acute heart failure: The STRONG-HF trial. Eur Heart J 2023;44:2947-2962. https://doi.org/10.1093/eurheartj/ehad335
Cautela J, Tartiere JM, Cohen-Solal A, Bellemain-Appaix A, Theron A, Tibi T, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur J Heart Fail 2020;22:1357-1365. https://doi.org/10.1002/ejhf.1835
Metra M, Pagnesi M, Claggett BL, Díaz R, Felker GM, McMurray JJV, et al. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: The GALACTIC-HF trial. Eur Heart J 2022;43:5006-5016. https://doi.org/10.1093/eurheartj/ehac293
Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Køber L, Squire IB, et al.; Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J 2013;34:1404-1413. https://doi.org/10.1093/eurheartj/ehs337
Arundel C, Lam PH, Gill GS, Patel S, Panjrath G, Faselis C, et al. Systolic blood pressure and outcomes in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol 2019;73:3054-3063. https://doi.org/10.1016/j.jacc.2019.04.022
Kapłon-Cieślicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, et al.; Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2022;24:335-350. https://doi.org/10.1002/ejhf.2408
Seferović PM, Polovina M, Adlbrecht C, Bělohlávek J, Chioncel O, Goncalvesová E, et al. Navigating between Scylla and Charybdis: Challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. Eur J Heart Fail 2021;23:1999-2007. https://doi.org/10.1002/ejhf.2378
Kimmoun A, Cotter G, Davison B, Takagi K, Addad F, Celutkiene J, et al. Safety, tolerability and efficacy of rapid optimization, helped by NT-proBNP and GDF-15, of heart failure therapies (STRONG-HF): Rationale and design for a multicentre, randomized, parallel-group study. Eur J Heart Fail 2019;21:1459-1467. https://doi.org/10.1002/ejhf.1575
Tomasoni D, Davison B, Adamo M, Davison B, Adamo M, Pagnesi M, et al. Safety indicators in patients receiving high-intensity care after hospital admission for acute heart failure: The STRONG-HF trial. J Card Fail. https://doi.org/10.1016/j.cardfail.2023.09.002 Published online ahead of print 09/10/23.
Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011;4:363-371. https://doi.org/10.1161/CIRCOUTCOMES.110.957951
Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: Prediction of survival in heart failure. Circulation 2006;113:1424-1433. https://doi.org/10.1161/CIRCULATIONAHA.105.584102
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574-1585. https://doi.org/10.1002/ejhf.813
Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, et al.; Heart Failure Association of the ESC (HFA). Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173-1184. https://doi.org/10.1093/eurjhf/hft134
Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 2019;73:2365-2383. https://doi.org/10.1016/j.jacc.2019.02.015
Jarjour M, Henri C, de Denus S, Fortier A, Bouabdallaoui N, Nigam A, et al. Care gaps in adherence to heart failure guidelines: Clinical inertia or physiological limitations? JACC Heart Fail 2020;8:725-738. https://doi.org/10.1016/j.jchf.2020.04.019
Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al.; OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296:2217-2226. https://doi.org/10.1001/jama.296.18.2217
Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: Classification and regression tree analysis. JAMA 2005;293:572-580. https://doi.org/10.1001/jama.293.5.572
Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al.; ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: The ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1242-1254. https://doi.org/10.1002/ejhf.890
Grand J, Miger K, Sajadieh A, Køber L, Torp-Pedersen C, Ertl G, et al. Systolic blood pressure and outcome in patients admitted with acute heart failure: An analysis of individual patient data from 4 randomized clinical trials. J Am Heart Assoc 2021;10:e022288. https://doi.org/10.1161/JAHA.121.022288
Rossello X, Bueno H, Gil V, Jacob J, Martín-Sánchez FJ, Llorens P, et al. Synergistic impact of systolic blood pressure and perfusion status on mortality in acute heart failure. Circ Heart Fail 2021;14:e007347. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007347
Cotter G, Davison BA, Butler J, Collins SP, Ezekowitz JA, Felker GM, et al. Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: An exploratory subgroup analysis of BLAST-AHF. Clin Res Cardiol 2018;107:170-181. https://doi.org/10.1007/s00392-017-1168-0
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al.; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380:539-548. https://doi.org/10.1056/NEJMoa1812851
Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, et al. Efficacy and safety of sacubitril/valsartan in high-risk patients in the PIONEER-HF trial. Circ Heart Fail 2021;14:e007034. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007034
Rao VN, Murray E, Butler J, Cooper LB, Cox ZL, Fiuzat M, et al. In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol 2021;78:2004-2012. https://doi.org/10.1016/j.jacc.2021.08.064
Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, et al. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 2022;24:431-441. https://doi.org/10.1002/ejhf.2397
Schrage B, Lund LH, Benson L, Braunschweig F, Ferreira JP, Dahlström U, et al. Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments: An analysis from the Swedish Heart Failure Registry. Eur J Heart Fail 2023;25:1132-1144. https://doi.org/10.1002/ejhf.2928
Matsue Y, Sama IE, Postmus D, Metra M, Greenberg BH, Cotter G, et al. Association of early blood pressure decrease and renal function with prognosis in acute heart failure. JACC Heart Fail 2021;9:890-903. https://doi.org/10.1016/j.jchf.2021.07.001
Grand J, Miger K, Sajadieh A, Køber L, Torp-Pedersen C, Ertl G, et al. Blood pressure drops during hospitalization for acute heart failure treated with serelaxin: A patient-level analysis of 4 randomized controlled trials. Circ Heart Fail 2022;15:e009199. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009199
Cotter G, Metra M, Davison BA, Jondeau G, Cleland JGF, Bourge RC, et al.; VERITAS Investigators. Systolic blood pressure reduction during the first 24 h in acute heart failure admission: Friend or foe? Eur J Heart Fail 2018;20:317-322. https://doi.org/10.1002/ejhf.889
Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, et al.; Pre-RELAX-AHF study group. Early drop in systolic blood pressure and worsening renal function in acute heart failure: Renal results of pre-RELAX-AHF. Eur J Heart Fail 2011;13:961-967. https://doi.org/10.1093/eurjhf/hfr060
Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: A prospective European study. Eur Heart J 2017;38:1883-1890. https://doi.org/10.1093/eurheartj/ehx026
Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, et al. Identifying optimal doses of heart failure medications in men compared with women: A prospective, observational, cohort study. Lancet 2019;394:1254-1263. https://doi.org/10.1016/S0140-6736(19)31792-1
D'Amario D, Rodolico D, Rosano GMC, Dahlström U, Crea F, Lund LH, et al. Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: Data from the Swedish Heart Failure Registry. Eur J Heart Fail 2022;24:871-884. https://doi.org/10.1002/ejhf.2477
Savarese G, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR, et al. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: A multinational observational study (US, UK and Sweden). Eur J Heart Fail 2021;23:1499-1511. https://doi.org/10.1002/ejhf.2271
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895-e1032. https://doi.org/10.1161/CIR.0000000000001063
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med 2022;28:568-574. https://doi.org/10.1038/s41591-021-01659-1
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire D, et al.; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117-128. https://doi.org/10.1056/NEJMoa2030183
Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol 2022;80:1302-1310. https://doi.org/10.1016/j.jacc.2022.07.021